| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049378984 |
| P356 | DOI | 10.1038/SJ.KI.5002553 |
| P698 | PubMed publication ID | 17898700 |
| P5875 | ResearchGate publication ID | 5945434 |
| P2093 | author name string | Johnston A | |
| Meyrier A | |||
| Saito T | |||
| Ponticelli C | |||
| Cattran DC | |||
| Choukroun G | |||
| Yoshikawa N | |||
| Heering P | |||
| Praga M | |||
| Hoyer PF | |||
| Alexopoulos E | |||
| Nachman P | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nephrotic syndrome | Q504790 |
| workshop | Q27556165 | ||
| idiopathy | Q594841 | ||
| P304 | page(s) | 1429-1447 | |
| P577 | publication date | 2007-09-26 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations | |
| P478 | volume | 72 |
| Q44201628 | 50 years of nephrotic syndrome in children, and hereafter |
| Q34455455 | Activation of NFAT signaling in podocytes causes glomerulosclerosis |
| Q33571864 | American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis |
| Q42639047 | Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy |
| Q87393373 | Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults |
| Q24202262 | Chinese herbal medicine Huangqi type formulations for nephrotic syndrome |
| Q34660324 | Circulating Permeability Factors in Idiopathic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis |
| Q82458069 | Clinical evaluation of chronic nephrotoxicity of long‐term cyclosporine A treatment in adult patients with steroid‐dependent nephrotic syndrome |
| Q34248343 | Controversies in the treatment of idiopathic membranous nephropathy |
| Q38085054 | Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults |
| Q41822387 | Cyclosporine A and steroid therapy in childhood steroid-resistant nephrotic syndrome |
| Q37553134 | Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial |
| Q43284411 | Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome |
| Q41968631 | Cyclosporine/ketoconazole reduces treatment costs for nephrotic syndrome |
| Q34659224 | Dystroglycan in the diagnosis of FSGS. |
| Q35546991 | Efficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adults |
| Q43485938 | Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome |
| Q36240947 | Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients |
| Q33803050 | Expression patterns of podocyte-associated mRNAs in patients with proliferative or non-proliferative glomerulopathies |
| Q38118221 | Glomerular diseases: membranous nephropathy--a modern view |
| Q53706807 | Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls. |
| Q46661390 | Idiopathic collapsing glomerulopathy in children |
| Q88076409 | Idiopathic membranous nephropathy in children treated with rituximab: report of two cases |
| Q37543422 | Idiopathic membranous nephropathy: management strategies |
| Q33715857 | IgA nephropathy with minimal change disease. |
| Q39570030 | Immune-mediated necrotizing myopathy, associated with antibodies to signal recognition particle, together with lupus nephritis: case presentation and management |
| Q34448821 | Infusion of autologous bone marrow mononuclear cells leads to transient reduction in proteinuria in treatment refractory patients with Idiopathic membranous nephropathy |
| Q37217446 | Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury |
| Q30835209 | Long-term data on tacrolimus treatment in lupus nephritis |
| Q37779802 | Management of idiopathic membranous nephropathy |
| Q36960657 | Membranous nephropathy in a patient with hereditary angioedema: a case report |
| Q47168526 | Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome |
| Q41688065 | Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor |
| Q93157356 | Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial |
| Q51529212 | Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. |
| Q38854254 | Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment |
| Q37828086 | New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome |
| Q26781358 | Nonimmunologic targets of immunosuppressive agents in podocytes |
| Q46736252 | Nuclear factor of activated T cells mediates RhoA-induced fibronectin upregulation in glomerular podocytes |
| Q64072166 | Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients |
| Q37812564 | Pathogenesis and therapy of focal segmental glomerulosclerosis: an update |
| Q38738516 | Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis |
| Q36284830 | Pharmacokinetics of cyclosporin--a microemulsion in children with idiopathic nephrotic syndrome |
| Q40185982 | Ponticelli regimen and nephrotic syndrome |
| Q33764995 | Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. |
| Q38110617 | Post-staphylococcal infection Henoch-Schönlein purpura nephritis: a case report and review of the literature |
| Q38164339 | Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor |
| Q27015909 | Pro: 'The usefulness of biomarkers in glomerular diseases'. The problem: moving from syndrome to mechanism--individual patient variability in disease presentation, course and response to therapy |
| Q44410073 | Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis |
| Q37146440 | Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy |
| Q36543103 | Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome |
| Q37953243 | Recent advances in the treatment of lupus nephritis |
| Q57945954 | References |
| Q55470645 | Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated. |
| Q37251705 | Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? |
| Q41027140 | Response to cyclosporine in steroid-resistant nephrotic syndrome: discontinuation is possible |
| Q33762358 | Revised guidelines for management of steroid-sensitive nephrotic syndrome |
| Q53675239 | Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. |
| Q42723614 | Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome |
| Q34324240 | Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial |
| Q36872799 | Stepwise treatment using corticosteroids alone and in combination with cyclosporine in korean patients with idiopathic membranous nephropathy |
| Q40390584 | Tacrolimus improves proteinuria remission in adults with cyclosporine A-resistant or -dependent minimal change disease |
| Q50968851 | The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. |
| Q41446914 | The long-term outlook to final outcome and steroid treatment results in children with idiopathic nephrotic syndrome |
| Q38285375 | The multifaceted aspects of refractory lupus nephritis |
| Q58177753 | The podocyte as a direct target of immunosuppressive agents |
| Q51337330 | The spectrum of histopathological lesions in children presenting with steroid-resistant nephrotic syndrome at a single center in Pakistan. |
| Q36280345 | Treatment of idiopathic membranous nephropathy |
| Q24632899 | Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel |
| Q26828859 | Treatment of primary FSGS in adults |
| Q47417726 | Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome |
| Q36294318 | Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children |
| Q39229298 | What are we missing in the clinical trials of focal segmental glomerulosclerosis? |
Search more.